Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Application of LiveSpo Navax in Treatment of Acute Respiratory Disease in Children Infected With Influenza Virus
NCT05378022Completed
- Sponsor
- National Hospital of Pediatrics
- Start
- Dec 2020
- Primary completion
- Mar 2022
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Randomised, single-blind trial of LiveSpo Navax in acute respiratory tract infection (ARTI) and influenza (2 arms), sponsored by National Hospital of Pediatrics. Primary endpoint: Percentage of patients with free respiratory symptoms. Started Dec 2020; status: completed.
02
Drugs
LiveSpo Navax
03
Conditions
acute respiratory tract infection (ARTI)influenza
Beyond the preview
Go deeper on NCT05378022.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05378022.